Advertisement

Topics

Alnylam Offers Flexible Value-Based Deals For Breakthrough RNAi Drug Onpattro

05:53 EDT 11 Aug 2018 | SCRIP

The commercial team is on board and ready to market the first FDA-approved RNAi therapeutic patisiran for hereditary transthyretin-mediated amyloidosis.

      

Related Stories

 

Original Article: Alnylam Offers Flexible Value-Based Deals For Breakthrough RNAi Drug Onpattro

NEXT ARTICLE

More From BioPortfolio on "Alnylam Offers Flexible Value-Based Deals For Breakthrough RNAi Drug Onpattro"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...